DDInter1042 DDInter607
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular events. It is the first T2DM drug approved to reduce major adverse cardiovascular events (MACE) risk in primary and secondary prevention populations.
Dulaglutide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Dulaglutide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mephentermine
Dulaglutide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Norgestrel
Dulaglutide {u} may lead to a major life threatening interaction when taken with {v} Bexarotene
Dulaglutide may cause a minor interaction that can limit clinical effects when taken with Amcinonide
Dulaglutide may cause a moderate interaction that could exacerbate diseases when taken with Mephentermine
Dulaglutide may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Dulaglutide may lead to a major life threatening interaction when taken with Bexarotene